Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Pfizer/Lilly And J&J Are Readying NGF Inhibitors For Phase III

23 Mar 2015

• By Jessica Merrill

Related Content

Regeneron, J&J, AstraZeneca Pull Plug On NGF Inhibitors In Development For Pain Indications

30 Dec 2010

A Painstaking Approach: Can Anti-NGFs Give Relief To Pharma Pipeline Woes?

17 May 2010

Future Appears Grim For Pfizer's Tanezumab With Ostearthritis Trial Stopped

24 Jun 2010

Anti-NGF Trials Might Resume With Very Narrow Patient Populations

19 Mar 2012

Pfizer Plans To Restart Tanezumab Trials In 2014

30 Jul 2013

Related Companies

Pfizer Inc.

Eli Lilly and Company

Johnson & Johnson

Regeneron Pharmaceuticals, Inc.

AstraZeneca PLC

Abbott

AbbVie Inc.

Sanofi

Additional Topics

Clinical Trials Regulation BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.